Antonello Lorenzini

Dr. Antonello Lorenzini

University of Bologna
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2019 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
VSValentina Salvestrini
Valentina Salvestrini
CSChristian Sell
Christian Sell
Antonello LorenziniAntonello Lorenzini
Antonello Lorenzini
Lines of evidence from several studies have shown that increases in life expectancy are now accompanied by increased disability rate. The expanded lifespan of the aging population imposes a challenge on the continuous increase of chronic disease. The prevalence of overweight and obesity is increasing at an alarming rate in many parts of the world. Further to increasing the onset of metabolic imbalances, obesity leads to reduced life span and affects cellular and molecular processes in a fashion resembling aging. Nine key hallmarks of the aging process have been proposed. In this review, we will review these hallmarks and discuss pathophysiological changes that occur with obesity, that are similar to or contribute to those that occur during aging. We present and discuss the idea that obesity, in addition to having disease-specific effects, may accelerate the rate of aging affecting all aspects of physiology and thus shortening life span and health span.

1 October 2004 in Mechanisms of Ageing and Development
Verified
Journal Article
Closed access
VCVincent J. Cristofalo
Vincent J. Cristofalo
Antonello LorenziniAntonello Lorenzini
Antonello Lorenzini
RAR.G. Allen
R.G. Allen
CTClaudio Torres
Claudio Torres
MTMaria Tresini
Maria Tresini

25 November 2019 in GeroScience
Verified
Journal Article
Open access
PDF file
CCChristina Lee Chung
Christina Lee Chung
ILIbiyonu Lawrence
Ibiyonu Lawrence
MHMelissa Hoffman
Melissa Hoffman
DEDareen Elgindi
Dareen Elgindi
KNKumar Nadhan
Kumar Nadhan
CSChristian Sell
Christian Sell
Aging is a major risk factor for the majority of human diseases, and the development of interventions to reduce the intrinsic rate of aging is expected to reduce the risk for age-related diseases including cardiovascular disease, cancer, and dementia. In the skin, aging manifests itself in photodamage and dermal atrophy, with underlying tissue reduction and impaired barrier function. To determine whether rapamycin, an FDA-approved drug targeting the mechanistic target of rapamycin (mTOR) complex, can reduce senescence and markers of aging in human skin, an exploratory, placebo-controlled, interventional trial was conducted in a clinical dermatology setting. Participants were greater than 40 years of age with evidence of age-related photoaging and dermal volume loss and no major morbidities. Thirty-six participants were enrolled in the study, and nineteen discontinued or were lost to follow-up. A significant (P = 0.008) reduction in p16INK4A protein levels and an increase in collagen VII protein levels (P = 0.0077) were observed among participants at the end of the study. Clinical improvement in skin appearance was noted in multiple participants, and immunohistochemical analysis revealed improvement in histological appearance of skin tissue. Topical rapamycin reduced the expression of the p16INK4A protein consistent with a reduction in cellular senescence. This change was accompanied by relative improvement in clinical appearance of the skin and histological markers of aging and by an increase in collagen VII, which is critical to the integrity of the basement membrane. These results indicate that rapamycin treatment is a potential anti-aging therapy with efficacy in humans.Trial registration ClinicalTrials.gov Identifier: NCT03103893.

1 October 2010 in Experimental Cell Research
Verified
Journal Article
Closed access
ABAlessandro Bitto
Alessandro Bitto
CSChristian Sell
Christian Sell
ECElizabeth Crowe
Elizabeth Crowe
Antonello LorenziniAntonello Lorenzini
Antonello Lorenzini
Marco MalagutiMarco Malaguti
Marco Malaguti
CTClaudio Torres
Claudio Torres

17 May 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DCDonatella Canistro
Donatella Canistro
Fabio VivarelliFabio Vivarelli
Fabio Vivarelli
SCSilvia Cirillo
Silvia Cirillo
CMClara Babot Marquillas
Clara Babot Marquillas
ABAnnamaria Buschini
Annamaria Buschini
MPMoreno Paolini
Moreno Paolini
Electronic cigarettes (e-cigs) are devices designed to deliver nicotine in a vaping solution rather than smoke and without tobacco combustion. Perceived as a safer alternative to conventional cigarettes, e-cigs are aggressively marketed as lifestyle-choice consumables, thanks to few restrictions and a lack of regulatory guidelines. E-cigs have also gained popularity among never-smokers and teenagers, becoming an emergent public health issue. Despite the burgeoning worldwide consumption of e-cigs, their safety remains largely unproven and it is unknown whether these devices cause in vivo toxicological effects that could contribute to cancer. Here we demonstrate the co-mutagenic and cancer-initiating effects of e-cig vapour in a rat lung model. We found that e-cigs have a powerful booster effect on phase-I carcinogen-bioactivating enzymes, including activators of polycyclic aromatic hydrocarbons (PAHs), and increase oxygen free radical production and DNA oxidation to 8-hydroxy-2′-deoxyguanosine. Furthermore, we found that e-cigs damage DNA not only at chromosomal level in peripheral blood, such as strand breaks in leucocytes and micronuclei formation in reticulocytes, but also at gene level such as point mutations in urine. Our results demonstrate that exposure to e-cigs could endanger human health, particularly among younger more vulnerable consumers.

1 November 2003 in Experimental Cell Research
Verified
Journal Article
Closed access
CTClaudio Torres
Claudio Torres
MFMary Kay Francis
Mary Kay Francis
Antonello LorenziniAntonello Lorenzini
Antonello Lorenzini
MTMaria Tresini
Maria Tresini
VCVincent J Cristofalo
Vincent J Cristofalo